{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:05Z","timestamp":1792644065788,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119357","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:21:43Z","timestamp":1790137303000},"page":"119357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent advances in the medicinal chemistry of HSV-1 inhibitors (2020\u20132025): Emerging targets, modalities, and translational challenges"],"prefix":"10.1016","volume":"320","author":[{"given":"Qiaomei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119357_bib1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119357_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/v14050862","article-title":"Fraternal twins: the enigmatic role of the immune system in alphaherpesvirus pathogenesis and latency and its impacts on vaccine efficacy","volume":"14","author":"Rouse","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119357_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2491","article-title":"Immunopathology of herpes simplex virus-associated neuroinflammation: unveiling the mysteries","volume":"34","author":"Hussain","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ejmech.2026.119357_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2024-056307","article-title":"Estimated global and regional incidence and prevalence of herpes simplex virus infections and genital ulcer disease in 2020: mathematical modelling analyses","volume":"101","author":"Harfouche","year":"2025","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.ejmech.2026.119357_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","article-title":"Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy","volume":"16","author":"Bacon","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.119357_bib6","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1128\/JVI.01139-08","article-title":"Herpes simplex virus replication: roles of viral proteins and nucleoporins in capsid-nucleus attachment","volume":"83","author":"Copeland","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119357_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2024.2425744","article-title":"An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application","volume":"15","author":"Su","year":"2024","journal-title":"Virulence"},{"key":"10.1016\/j.ejmech.2026.119357_bib8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14760584.2021.1960162","article-title":"Current vaccine approaches and emerging strategies against herpes simplex virus (HSV)","volume":"20","author":"Wijesinghe","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejmech.2026.119357_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.coviro.2011.06.003","article-title":"Herpesvirus capsid assembly: insights from structural analysis","volume":"1","author":"Brown","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejmech.2026.119357_bib10","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/v5071758","article-title":"Chromatin dynamics during lytic infection with herpes simplex virus 1","volume":"5","author":"Conn","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119357_bib11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1574-6976.2011.00320.x","article-title":"The molecular basis of herpes simplex virus latency","volume":"36","author":"Nicoll","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.119357_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212472","article-title":"Vistas in signaling pathways implicated in HSV-1 reactivation","volume":"25","author":"Papavassiliou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119357_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2016.01.013","article-title":"HSV antivirals \u2013 current and future treatment options","volume":"18","author":"Birkmann","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejmech.2026.119357_bib14","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/v13071228","article-title":"Current drugs to treat infections with Herpes simplex Viruses-1 and -2","volume":"13","author":"Sadowski","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119357_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01426-20","article-title":"Population pharmacokinetics of intravenous and oral acyclovir and oral valacyclovir in pediatric population to optimize dosing regimens","volume":"64","author":"Abdalla","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119357_bib16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dkv285","article-title":"Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2","volume":"71","author":"Sauerbrei","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.119357_bib17","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/jm00128a012","article-title":"Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties","volume":"32","author":"Harnden","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119357_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115322","article-title":"Acyclovir resistance in herpes simplex viruses: prevalence and therapeutic alternatives","volume":"206","author":"Schalkwijk","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119357_bib20","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1517\/14656566.5.12.2567","article-title":"Docosanol: a topical antiviral for herpes labialis","volume":"5","author":"Leung","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119357_bib22","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.119357_bib45","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3390\/v13081547","article-title":"Amenamevir, a helicase-primase inhibitor, for the optimal treatment of Herpes zoster","volume":"13","author":"Shiraki","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119357_bib25","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1021\/acs.jmedchem.2c00668","article-title":"Discovery, chemistry, and preclinical development of Pritelivir, a novel treatment option for acyclovir-resistant Herpes simplex virus infections","volume":"65","author":"Birkmann","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119357_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119357_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of Herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119357_bib21","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.1073\/pnas.88.23.10825","article-title":"Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex","volume":"88","author":"Katz","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119357_bib23","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119357_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac494","article-title":"Single-dose, patient-initiated amenamevir therapy for recurrent genital herpes: a phase 3, randomized, double-blind, placebo-controlled study","volume":"9","author":"Kawashima","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119357_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/13543776.2025.2548925","article-title":"Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of assembly biosciences Inc","volume":"35","author":"Gege","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119357_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/ph15030361","article-title":"Identifying HSV-1 inhibitors from natural compounds via virtual screening targeting surface glycoprotein D","volume":"15","author":"Wu","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119357_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4155\/fmc-2023-0210","article-title":"Novel xylenyl-spaced bis-thiazoles\/thiazines: synthesis, biological profile as herpes simplex virus type 1 inhibitors and in silico simulations","volume":"16","author":"Kassab","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119357_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-025-09438-5","article-title":"A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2","volume":"646","author":"Vollmer","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119357_bib36","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1038\/s41564-025-02153-x","article-title":"Prefusion structure, evasion and neutralization of HSV-1 glycoprotein B","volume":"10","author":"Roark","year":"2025","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119357_bib37","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/s41467-025-58669-7","article-title":"A potent protective bispecific nanobody targeting Herpes simplex virus gD reveals vulnerable epitope for neutralizing","volume":"16","author":"Hu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119357_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116063","article-title":"Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease","volume":"44","author":"Lee","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119357_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202400120","article-title":"Mucin\u2010inspired polymeric fibers for Herpes simplex virus type 1 inhibition","volume":"24","author":"Arenhoevel","year":"2024","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ejmech.2026.119357_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0166-3542(01)00208-X","article-title":"Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses","volume":"54","author":"Brideau","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119357_bib47","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1038\/s41467-021-23312-8","article-title":"Structural understanding of non-nucleoside inhibition in an elongating herpesvirus polymerase","volume":"12","author":"Hayes","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119357_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400629","article-title":"Discovery of novel Pyrido[2,3-b]Pyrazine human cytomegalovirus polymerase inhibitors with broad spectrum antiherpetic activity and reduced hERG inhibition","volume":"20","author":"Bai","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119357_bib49","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1021\/acsmedchemlett.4c00117","article-title":"Discovery of broad-spectrum herpes antiviral oxazolidinone amide derivatives and their structure\u2013activity relationships","volume":"15","author":"Plotkin","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119357_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03226-21","article-title":"Two-metal ion-dependent enzymes as potential antiviral targets in human herpesviruses","volume":"13","author":"DiScipio","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.ejmech.2026.119357_bib52","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/v17091153","article-title":"The triplex-centric assembly and maturation of the herpesvirus procapsid","volume":"17","author":"Heymann","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2026.119357_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105604","article-title":"Novel inhibitors of HSV-1 protease effective in vitro and in vivo","volume":"213","author":"Pachota","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119357_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.797279","article-title":"Hsp90 inhibitors prevent HSV-1 replication by directly targeting UL42-Hsp90 complex","volume":"12","author":"Qin","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119357_bib56","doi-asserted-by":"crossref","first-page":"17014","DOI":"10.1021\/acs.jafc.5c04281","article-title":"Ellagic acid and the metabolite urolithin A suppress HSV-1 infection and brain inflammation by targeting casein kinase CK2","volume":"73","author":"Sun","year":"2025","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2026.119357_bib58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11427-023-2627-8","article-title":"Genome-wide CRISPR screens identify CLC-2 as a drug target for anti-herpesvirus therapy: tackling herpesvirus drug resistance","volume":"68","author":"Yang","year":"2025","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejmech.2026.119357_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ncomms1571","article-title":"Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion","volume":"2","author":"Zhang","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119357_bib29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.2001.1326","article-title":"Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b","volume":"294","author":"Rux","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.ejmech.2026.119357_bib30","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1128\/JVI.80.8.4038-4046.2006","article-title":"Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody","volume":"80","author":"Hook","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119357_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01852-19","article-title":"Glycoprotein C of Herpes simplex virus 1 shields glycoprotein B from antibody neutralization","volume":"94","author":"Komala Sari","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119357_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00090-25","article-title":"Herpes simplex virus 1 envelope glycoprotein C shields glycoprotein D to protect virions from entry-blocking antibodies","volume":"99","author":"Hull","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2026.119357_bib40","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.2741\/1964","article-title":"The two helicases of herpes simplex virus type 1 (HSV-1)","volume":"11","author":"Chattopadhyay","year":"2006","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2026.119357_bib41","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.cell.2025.11.041","article-title":"Mechanisms of HSV-1 helicase-primase inhibition and replication fork complex assembly","volume":"189","author":"Yu","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119357_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41421-025-00855-4","article-title":"Structural and mechanistic insights into the herpes simplex virus type 1 helicase-primase primosome","volume":"11","author":"Wu","year":"2025","journal-title":"Cell Discov."},{"key":"10.1016\/j.ejmech.2026.119357_bib43","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1038\/s41564-025-02168-4","article-title":"Structural and mechanistic insights into herpesvirus helicase\u2013primase and its therapeutic inhibitors","volume":"10","author":"Yao","year":"2025","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119357_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adz1989","article-title":"Structural basis of herpesvirus helicase-primase inhibition by pritelivir and amenamevir","volume":"11","author":"Baranovskiy","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.119357_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202508006","article-title":"Discovery of a baloxavir\u2010inspired endonuclease inhibitor that prevents Herpes simplex virus 1 replication in cell culture and in vivo","author":"Andreu","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119357_bib55","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1248\/bpb.b21-00054","article-title":"NSC23766 and Ehop016 suppress Herpes simplex Virus-1 replication by inhibiting Rac1 activity","volume":"44","author":"Zhang","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2026.119357_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106244","article-title":"Suppression of herpes simplex virus type 1 replication by Pin1 inhibitors: insights from H-77 and novel compounds","volume":"241","author":"Elsayed","year":"2025","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119357_bib59","doi-asserted-by":"crossref","first-page":"13321","DOI":"10.1021\/acs.jmedchem.4c03034","article-title":"Discovery of novel piperazinone-fused hydroxypyridinones inhibiting Herpes simplex virus gene transcription and viral replication","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119357_bib60","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1021\/acs.jmedchem.5c00256","article-title":"Discovery of phloroglucinol derivatives as a new type of nonnucleoside inhibitors with anti-herpes simplex virus type 1 activity","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119357_bib61","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.6c01234","article-title":"Exploring privileged structure repurposing: target similarity as a catalyst for cross-species drug discovery","author":"Du","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119357_bib62","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.apsb.2026.02.007","article-title":"Cryptic pockets in proteins: harnessing conformational dynamics for rational drug design","author":"Ma","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119357_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110378","article-title":"Targeting novel sites represents an effective strategy for combating drug resistance","volume":"36","author":"Du","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119357_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118208","article-title":"Antiviral strategies based on targeted protein degradation: an overview of the literature and future outlook","volume":"301","author":"Zhou","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119357_bib65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15212\/AMM-2023-0019","article-title":"Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality","volume":"2","author":"Zhou","year":"2023","journal-title":"Acta Materia Medica"},{"key":"10.1016\/j.ejmech.2026.119357_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscia.2025.100094","article-title":"Conquering viral drug resistance: structural and mechanistic paradigms for antiresistance drug design","volume":"3","author":"Wang","year":"2025","journal-title":"Pharm. Sci. Adv."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:24:14Z","timestamp":1792643054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":66,"alternative-id":["S0223523426008020"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119357","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the medicinal chemistry of HSV-1 inhibitors (2020\u20132025): Emerging targets, modalities, and translational challenges","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119357"}}